What is it about?
The joint investigation carried out here compares, in a melanoma xenograft model, the effects of the original EphB4 receptor tyrosine kinase inhibitor NVP-BHG712 with a regioisomer of the compound falsely sold by various commercial suppliers under this name.
Featured Image
Read the Original
This page is a summary of: The Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitor NVP-BHG712: Effects of Regioisomers on Tumor Growth, Perfusion, and Hypoxia in EphB4-Positive A375 Melanoma Xenografts, Molecules, November 2020, MDPI AG,
DOI: 10.3390/molecules25215115.
You can read the full text:
Contributors
The following have contributed to this page
